Kisspeptin

Summary

Kisspeptin is the signal that starts puberty. That is not a marketing line — it is what the genetics show. In 2003 a New England Journal of Medicine study found that people carrying loss-of-function mutations in GPR54, the receptor kisspeptin acts on, fail to enter puberty, and mice engineered without the same receptor have the same problem. Kisspeptin sits one level above GnRH in the reproductive hierarchy: it tells the hypothalamus to release GnRH, which tells the pituitary to release LH and FSH, which tell the gonads to work.

Unusually for this site, the human research is both real and encouraging. A group at Imperial College London has run it as an IVF trigger — where 60 women at high risk of ovarian hyperstimulation syndrome had 95% oocyte maturation and not one developed moderate, severe or critical OHSS — and as a treatment for low sexual desire in men, where a randomized crossover trial found it changed brain activity in the sexual-processing network and increased physiological arousal.

Two things keep the grades honest. Every one of those doses went in as an intravenous infusion or injection inside a research centre. And the material sold online is usually kisspeptin-10, the short fragment, which in mice has a four-minute half-life against kisspeptin-54's thirty-two, and which — unlike KP-54 — failed to activate the GnRH neurons it is supposed to be reaching.

What people use it for

Libido is the driver, and it is unusually well-founded as premises go: there is a real randomized trial in men with low sexual desire, published in a JAMA journal, reporting real effects. Coverage of that trial is what put kisspeptin on the peptide map.

Testosterone and fertility follow from the mechanism. Because kisspeptin acts upstream of GnRH, it is discussed as a way to stimulate the whole axis without shutting anything down — the same conversation that surrounds HCG and gonadorelin, one rung higher up.

Fertility treatment is the use with the most developed clinical programme, though almost nobody buying kisspeptin online is doing IVF.

Human evidence

The biology is settled. The 2003 GPR54 paper studied a consanguineous family whose members never developed puberty, found a homozygous L148S mutation in the receptor, confirmed the functional defect in transfected cells, and built a Gpr54-deficient mouse that reproduced the phenotype — small testes in males, absent follicular maturation in females — while still responding normally to gonadotropins and GnRH given from outside. Further loss-of-function mutations in unrelated families have been reported since. That kisspeptin signalling is required for puberty and reproduction is about as established as anything in reproductive endocrinology, which is why that claim grades S+.

Note carefully what it is a claim about: the system, not the injection. "Your body needs this hormone" and "injecting more of it does something you want" are different statements, and the rest of this page is about the second one.

IVF trigger — the strongest applied result. Standard IVF uses HCG to trigger final egg maturation, and HCG's long action is part of what drives ovarian hyperstimulation syndrome, a complication that can be life-threatening. Kisspeptin's shorter action makes it a candidate for a safer trigger. In a Phase 2 open-label randomized trial, 60 women at high risk of OHSS received a single injection of kisspeptin-54 at one of four doses. Oocyte maturation occurred in 95% of women. Across all doses, biochemical pregnancy, clinical pregnancy and live-birth rates per transfer (51 transfers) were 63%, 53% and 45%. And no woman developed moderate, severe or critical OHSS. A subsequent Phase 2 randomized controlled trial found a second dose improved oocyte maturation further in the same high-risk population.

That is a genuinely promising result on a problem that matters. It is also Phase 2, open-label in the first trial, single-centre, and has not led to an approved product in the decade since — which is what separates S from S+.

Low sexual desire in men. A double-blind, two-way crossover, placebo-controlled randomized trial gave 37 men with hypoactive sexual desire disorder (32 completed) kisspeptin-54 by intravenous infusion at 1 nmol/kg/h for 75 minutes, against rate-matched placebo, on two visits at least a week apart. While viewing sexual videos in an fMRI scanner, kisspeptin significantly modulated activity across the sexual-processing network (mean absolute change, Cohen's d = 0.81; 95% CI 0.41–1.21; P = .003). Secondary outcomes included increased penile tumescence in response to sexual stimuli — up to 56% more than placebo (mean difference 0.28 units; 95% CI 0.04–0.52; P = .02) — and increased self-reported happiness about sex (mean difference 0.63 points; 95% CI 0.10–1.15; P = .02).

Earlier work from the same group found kisspeptin enhanced limbic brain activity in 29 healthy men, and a 2018 study reported changes in resting brain connectivity.

Read the trial for what it is. The primary outcome was brain activity on fMRI, not sexual function in daily life. The arousal and mood findings were secondary, with confidence intervals whose lower bounds sit close to zero. Thirty-two men completed. And the whole thing was measured during a 75-minute intravenous infusion in a scanner. The authors' own conclusion is that kisspeptin "has potential as the first pharmacological treatment for men with low sexual desire" — potential, which is the correct word and not the one that survives into a product listing. Real randomized human evidence, narrow and small: S.

What has not been shown. No trial has tested self-administered kisspeptin, by any route, for libido or anything else. No trial has run longer than a single infusion or injection for the sexual endpoints. No regulator has approved it. The gap between "an infusion changed fMRI signal and tumescence over 75 minutes in a lab" and "a vial you inject at home works for low libido" is not a small one, and it has never been bridged by a study. C.

Animal / preclinical evidence

The animal work matters here for one specific and practical reason: it is why kisspeptin-54 and kisspeptin-10 are not interchangeable.

Kisspeptins come in several lengths — 54, 14, 13 and 10 amino acids — that share the same C-terminal 10-amino-acid business end. It is tempting to conclude that the short one is the active core and the rest is packaging. A 2017 mouse study tested exactly that. After systemic injection, KP-54 sustained LH release far longer than KP-10. Measured half-lives in the bloodstream were roughly 32 minutes for KP-54 and 4 minutes for KP-10. When the researchers compensated by injecting KP-10 every 10 minutes for an hour, they still could not reproduce the sustained LH rise from a single KP-54 injection — so clearance alone does not explain the difference. And when they looked at whether each peptide activated GnRH neurons behind the blood-brain barrier, only KP-54 did.

This is a mouse study and is graded as such. But it is the direct mechanistic reason the Imperial trials use KP-54, and it means a vial of KP-10 is not a cheaper version of the trial drug. That is the second C.

Anecdotal / community reports

Low-confidence. These are community reports, not evidence. Not medical guidance.

Kisspeptin discussion online leans heavily on the 2023 HSDD trial, usually reduced to a single sentence about improved arousal, with the intravenous route, the 75-minute infusion, the fMRI primary endpoint and the 32 completers all dropped along the way.

Reports of subjective libido effects after subcutaneous self-injection are common. Nothing in the published literature speaks to that route, that setting, or that peptide length, so there is no way to say whether reported effects reflect the drug, the expectation created by the headlines, or something else. A well-publicised trial makes a compound more susceptible to expectancy effects, not less.

Doses used in published studies

Context only — not a recommendation. PeptideIQ Base does not provide dosing advice.

Look at the route before the number. The sexual-desire trial used kisspeptin-54 at 1 nmol/kg/hour as an intravenous infusion over 75 minutes, in a research facility, with a rate-matched placebo and an MRI scanner. The IVF trial used a single injection of kisspeptin-54 at 3.2 to 12.8 nmol/kg, with egg retrieval 36 hours later, in a hospital IVF unit.

Both are dosed in nanomoles per kilogram, which does not convert to a microgram figure on a vial label without knowing the exact peptide and its molecular weight — and kisspeptin-54 and kisspeptin-10 have very different ones. Any milligram or microgram protocol circulating for self-injection was not derived from these trials, because these trials did not produce one.

There is no established dose of kisspeptin for libido, testosterone, or fertility outside a research protocol.

Safety & side effects

The safety picture is limited by design rather than reassuring. Kisspeptin has been given to a few hundred people, in single infusions or single injections, at academic centres, under monitoring, mostly by one research group. Within that setting the trials proceeded through Phase 2 without reports of serious drug-related harm, and the IVF programme's headline safety finding is a positive one: no woman in the 60-patient trial developed moderate, severe or critical OHSS, which is the complication the approach was designed to avoid.

What does not exist is any of the following: repeated or long-term dosing data, data on subcutaneous self-administration, data in women outside fertility treatment, data in men outside single-infusion studies, and any data at all on kisspeptin-10 given chronically to healthy people. The absence of reported harm in short single-dose research is not evidence of safety in indefinite home use — it is the absence of anyone having looked.

One consideration follows from the mechanism rather than from a safety report. Kisspeptin drives the entire reproductive axis from the top. GnRH-based drugs are well known to produce the opposite of stimulation when given continuously rather than in pulses — sustained receptor stimulation downregulates the axis. Whether repeated kisspeptin dosing behaves that way in humans has not been established either way, and it is precisely the question that a home-use protocol would be answering by accident.

Regulatory / legal status

Kisspeptin is not approved anywhere for anything. No FDA approval, no approval from any other regulator, no marketed product, and no prescription route. Every dose described on this page was administered inside a clinical trial.

Material sold online is research-chemical supply and, in most listings, is kisspeptin-10 rather than the kisspeptin-54 used in the trials — a distinction the animal pharmacology above says is not cosmetic. Nothing about that supply has been reviewed for identity, purity or sterility.

In sport, kisspeptin and its agonist analogues are named explicitly on the WADA Prohibited List under S2.2.1, testosterone-stimulating peptides in males — the same sub-section that lists chorionic gonadotrophin, luteinizing hormone and the GnRH analogues. Everything in class S2 is prohibited at all times, in and out of competition, and is a non-Specified Substance.

Status can change and varies by country; this is not legal or medical advice.

Podcast / media mentions

Kisspeptin arrived in wellness and men's-health coverage on the back of the 2023 HSDD trial, and the coverage has generally been accurate about the finding and silent about its shape. "Kisspeptin boosts arousal in men with low libido" is a fair summary of the result. It is not a fair summary of a 75-minute intravenous infusion in an MRI scanner with brain activity as the primary endpoint and 32 completers.

This is a better problem to have than most compounds on this site present. There is a real trial here, run by a serious group, published in a serious journal, and its authors describe the drug as having potential to become a treatment. The distance between that and a purchasable product is a Phase 3 programme, a route that someone can actually use at home, and a regulator — none of which exists yet. Kisspeptin is a good candidate that has not finished the process, and the honest version of the story is that the process is what turns a candidate into a medicine.